SGLT2 inhibitors in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis

Back

EAPC Premium Access

SGLT2 inhibitors in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis

Session: Rapid fire abstracts session 1 - Secondary Prevention and Rehabilitation

Topic: Pharmacotherapy

Speaker: Doctor V. Tsampasian (Norwich, GB)

Event: ESC Preventive Cardiology 2022

Congress Presentation

Add to my library

About the speaker

Doctor Vasiliki Tsampasian

University of East Anglia, Norwich (United Kingdom of Great Britain & Northern Ireland)

2 presentations

0 follower

4 more presentations in this session

Ventricular-arterial coupling derived from proximal aortic stiffness: impact on aerobic capacity across the heart failure spectrum.

Speaker: Doctor N. Pugliese (Pisa, IT)

High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort

Speaker: Doctor P. Wang (Beijing, CN)

Insomnia was associated with increased risk of recurrent cardiovascular events in coronary heart disease patients

Speaker: Mr L. Frojd (Drammen, NO)

Effects of once-weekly semaglutide on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial

Speaker: Doctor A. Kolkailah (Dallas, US)

Access the full session

Rapid fire abstracts session 1 - Secondary Prevention and Rehabilitation

Speakers: Doctor V. Tsampasian, Doctor N. Pugliese, Doctor P. Wang, Mr L. Frojd, Doctor A. Kolkailah

Access

About the event

ESC Preventive Cardiology 2022

7 April - 9 April 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources